FOXP3 and Schwartz-Jampel syndrome: No significant differences in splenic Foxp3+ CD4+ T cells or Foxp3+ CD25+ CD4+ T cells were observed relative to vehicle-treated mice (Fig. 4A, B); however, the LL 301 medium dose effectively enhanced Foxp3+ CD25+ CD4+ T cells relative to WT LL-treated SjS females (Fig. 4B).